Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials

Vaccine

Volumn 34, Issue 35, 2016, Pages 4092-4102

  Moa, Aye M ^a   Chughtai, Abrar A ^a   Muscatello, David J ^a   Turner, Robin M ^a   MacIntyre, C Raina ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Immunogenicity; Influenza vaccine; Intramuscular; QIV; Quadrivalent

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ADULT; BELL PALSY; CELL LINEAGE; COST EFFECTIVENESS ANALYSIS; COUGHING; CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA B; INFLUENZA VACCINATION; INJECTION SITE PAIN; META ANALYSIS; MYALGIA; NONHUMAN; OPTIC NEURITIS; OROPHARYNX PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; SEROCONVERSION; SKIN REDNESS; SKIN SWELLING; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; IMMUNOLOGY; INFLUENZA, HUMAN; VACCINE IMMUNOGENICITY;

ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA VACCINES; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROCONVERSION; VACCINES, INACTIVATED;

EID: 84991242608     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.064     Document Type: Review

References (48)

1. [1] CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(No. RR-8):1–68.
2. [2] WHO. World Health Organization. Influenza (Seasonal). Available at < http://www.who.int/mediacentre/factsheets/fs211/en/> [Accessed 14 January, 2016].
3. [3] Simonsen, L., Spreeuwenberg, P., Lustig, R., et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. PLoS Med, 10(11), 2013, e1001558.
4. [4] Hannoun, C., The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 12:9 (2013), 1085–1094.
5. [5] Ambrose, C.S., Levin, M.J., The rationale for quadrivalent influenza vaccines. Human Vaccines Immunother 8:1 (2012), 81–88.
6. [6] McCullers, J.A., Saito, T., Iverson, A.R., Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 78:23 (2004), 12817–12828.
7. [7] WHO, Influenza. Vaccines, 2015 Available at: [Accessed 19 November, 2015].
8. [8] Caini, S., Huang, Q.S., Ciblak, M., et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses 9:Suppl. 1 (2015), 3–12.
9. [9] Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:1 (2012), 36–44.
10. [10] Skowronski, D.M., Janjua, N.Z., Sabaiduc, S., et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011–2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 210:1 (2014), 126–137.
11. [11] Lo, Y.C., Chuang, J.H., Kuo, H.W., et al. Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011–12 season. PLoS ONE, 8(3), 2013, e58222.
12. [12] Janjua, N.Z., Skowronski, D.M., De Serres, G., et al. Estimates of influenza vaccine effectiveness for 2007–2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis 205:12 (2012), 1858–1868.
13. [13] McLean, H.Q., Thompson, M.G., Sundaram, M.E., et al. Influenza vaccine effectiveness in the united states during 2012–2013: variable protection by age and virus type. J Infect Dis, 2014.
14. [14] Rodriguez Weber, M.A., Claeys, C., Aranza Doniz, C., et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18–47 months of age. Pediat Infect Dis J 33:12 (2014), 1262–1269.
15. [15] Kieninger, D., Sheldon, E., Lin, W.Y., et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >18 years. BMC Infect Dis, 13(1), 2013, 343.
16. [16] Greenberg, D.P., Robertson, C.A., Noss, M.J., Blatter, M.M., Biedenbender, R., Decker, M.D., Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 31:5 (2013), 770–776.
17. [17] Domachowske, J.B., Pankow-Culot, H., Bautista, M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis 207:12 (2013), 1878–1887.
18. [18] Tinoco, J.C., Pavia-Ruz, N., Cruz-Valdez, A., et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ⩾18 years: a phase III, randomized trial. Vaccine 32:13 (2014), 1480–1487.
19. [19] Taksler, G.B., Rothberg, M.B., Cutler, D.M., Association of influenza vaccination coverage in younger adults with influenza-related illness in the elderly. Clin Infect Dis, 2015, 1–9 [Published online, September 9, 2015].
20. [20] Cohen, S.A., Chui, K.K.H., Naumova, E.N., Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002–2006. J Am Geriatr Soc 59:2 (2011), 327–332.
21. [21] Glezen, W.P., Herd protection against influenza. J Clin Virol 37:4 (2006), 237–243.
22. [22] Lee, B.Y., Bartsch, S.M., Willig, A.M., The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 30:52 (2012), 7443–7446.
23. [23] Eichner, M., Schwehm, M., Hain, J., et al. 4Flu-an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis, 14, 2014.
24. [24] Beran, J., Peeters, M., Dewe, W., Raupachova, J., Hobzova, L., Devaster, J.M., Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis, 13(1), 2013, 224.
25. [25] Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21:11 (2002), 1539–1558.
26. [26] Review Manager (RevMan), version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
27. [27] Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed), 343, 2011, d5928.
28. [28] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research Ed), 339, 2009, b2535.
29. [29] Pepin, S., Donazzolo, Y., Jambrecina, A., Salamand, C., Saville, M., Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 31:47 (2013), 5572–5578.
30. [30] Regan, A.K., Tracey, L., Gibbs, R., Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. Vaccine 33:46 (2015), 6149–6151.
31. [31] Hobson, D., Curry, R.L., Beare, A.S., Ward-Gardner, A., The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 70:4 (1972), 767–777.
32. [32] Coudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., Ecochard, R., Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 10:18 (2010), 1–11.
33. [33] Committee for Proprietary Medicinal Products (CPMP): Note for guidance on harmonisation of requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products < http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf>.
34. [34] Center for Biologics Evaluation and Research (CBER). Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Food and Drug Administration (FDA) < http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf>.
35. [35] Skowronski, D.M., Janjua, N.Z., Sabaiduc, S., et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011–2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis, 2014.
36. [36] Puzelli, S., Frezza, F., Fabiani, C., et al. Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001–02, 2002–03, and 2003–04 seasons. J Med Virol 74:4 (2004), 629–640.
37. [37] Ansaldi, F., D'Agaro, P., de Florentiis, D., et al. Molecular characterization of influenza B viruses circulating in northern Italy during the 2001–2002 epidemic season. J Med Virol 70:3 (2003), 463–469.
38. [38] Camilloni, B., Neri, M., Lepri, E., Iorio, A.M., Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 27:31 (2009), 4099–4103.
39. [39] Pyhälä, R., Kleemola, M., Kumpulainen, V., et al. Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages. Vaccine 10:9 (1992), 631–636.
40. [40] Barr, I.G., Komadina, N., Durrant, C., Sjogren, H., Hurt, A.C., Shaw, R.P., Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell Quart Rep 30:3 (2006), 350–357.
41. [41] Tricco, A.C., Chit, A., Soobiah, C., et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med, 11(153), 2013.
42. [42] Thommes, E.W., Ismaila, A., Chit, A., Meier, G., Bauch, C.T., Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis, 15, 2015, 465.
43. [43] Meier, G., Gregg, M., Nautrup, B.P., Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK. J Med Econ 18:9 (2015), 746–761.
44. [44] You, J.H., Ming, W.K., Chan, P.K., Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis, 14, 2014, 618.
45. [45] Van Bellinghen, L.A., Meier, G., Van Vlaenderen, I., The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS ONE, 9(6), 2014.
46. [46] Clements, K.M., Meier, G., McGarry, L.J., Pruttivarasin, N., Misurski, D.A., Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccines Immunother 10:5 (2014), 1171–1180.
47. [47] Quinn, E., Jit, M., Newall, A.T., Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert Rev Pharmacoeconomics Out Res 14:3 (2014), 425–435.
48. [48] Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., Weiskopf, D., Grubeck-Loebenstein, B., Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 46:7 (2008), 1078–1084.